Partners Wealth Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.14M Buy
4,438
+2,303
+108% +$2.72M 0.66% 29
2026
Q2
$2.56M Sell
2,135
-572
-21% -$584K 2.51% 8
2026
Q1
$2.49M Sell
2,707
-104
-4% -$105K 2.57% 8
2025
Q4
$3.02M Sell
2,811
-137
-5% -$131K 3.15% 6
2025
Q3
$2.25M Buy
2,948
+44
+2% +$32.7K 2.22% 10
2025
Q2
$2.34M Hold
2,904
– – 2.66% 4
2025
Q1
$2.4M Sell
2,904
-113
-4% -$94K 2.72% 4
2024
Q4
$2.33M Buy
+3,017
New +$2.5M 2.65% 5

Other funds holding LLY

Partners Wealth Management's LLY Position: Q3 2026 in Review

Partners Wealth Management increased its Eli Lilly (LLY) stake by 108% in Q3 2026, buying an estimated $2.72M and bringing the position to 4,438 shares worth $5.14M. The position accounts for 0.66% of the portfolio, ranked #29.

Partners Wealth Management first reported a position in LLY in Q4 2024 and has held it in 8 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Partners Wealth Management held 4,438 shares of Eli Lilly worth $5.14M as of Q3 2026.
  • Partners Wealth Management bought 2,303 Eli Lilly shares in Q3 2026, an estimated $2.72M.
  • Eli Lilly made up 0.66% of Partners Wealth Management's portfolio in Q3 2026, its #29 holding.
  • Partners Wealth Management first reported a position in Eli Lilly in Q4 2024 and has held it in 8 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Partners Wealth Management's 13F filing for Q3 2026, filed 28 Oct 2026.